NEW YORK, Feb 22 - Bayer and Curagen received clearance from the Federal Trade Commission Thursday to complete a $124 million functional genomics deal and a $1.34 billion deal to jointly develop obesity drugs.

The proposed deal did not violate the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the FTC said. Following the approval, Bayer completed the purchase of $85 million in Curagen common stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.